VJHemOnc Podcast

At present, four types of chimeric antigen receptor T-cell (CAR-T) therapy are FDA approved for specific types of lymphoma: for relapsed or refractory (R/R) mantle cell lymphoma, brexucabtagene autoleucel, for R/R follicular lymphoma, axicabtagene ciloleucel, and for some aggressive forms of non-Hodgkin lymphoma, axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel. Despite these approvals, progression of disease and toxicity remain unresolved concerns associated with CAR-T therapy which are currently being investigated.

In this podcast, Caron Jacobson of the Dana-Farber Cancer Institute, Boston, MA, Stephen Schuster of the Perelman School of Medicine, Philadelphia, PA, Jeremy Abramson of the Massachusetts General Hospital Cancer Center, Boston, MA, Frederick Locke of the H. Lee Moffitt Cancer & Research Institute, Tampa, FL, David Miklos of Stanford University, Stanford, CA, Mazyar Shadman of the Fred Hutchinson Cancer Research Center, Seattle, WA, and Sonali Smith of the University of Chicago, Chicago, IL, discuss the latest updates on CAR-T therapy for the treatment of lymphoma.

The post Latest updates on CAR-T therapy for lymphoma appeared first on VJHemOnc.

Although classical Hodgkin lymphoma has a high cure and overall survival rate, the treatment of relapsed/refractory disease, treatment-related adverse events, impacts on quality of life and poor outcomes in older patients present ongoing unmet needs. Much research is currently focused on risk stratification, such as with positive emission tomography (PET) scans, to identify patients who are at low- or high-risk of recurrence and enable the use of risk-adapted approaches. Furthermore, longer-term follow-up data from trials of novel immunotherapy combinations in the frontline setting have recently been presented which demonstrate durable remissions and may reduce the risk of relapse for patients with classical Hodgkin lymphoma.

In this podcast, Julia Driessen, MBBS, University of Amsterdam, Amsterdam, The Netherlands; Ann LaCasce, MD, MMSc, Dana-Farber Cancer Institute, Boston, MA; Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, and Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, share updates on the use of PET in the treatment and management of Hodgkin lymphoma, as well as five-year follow-up data from the ECHELON-1 and CheckMate 205 trials, as presented at the 2021 International Conference on Malignant Lymphoma (ICML) and this year’s European Hematology Association (EHA) Congress.

The post EHA & ICML 2021: updates in Hodgkin lymphoma appeared first on VJHemOnc.

Hematopoietic stem cell transplantation (HSCT) is used as a treatment option for a wide variety of hematological disorders. Graft-versus-host disease (GvHD) is a systemic disorder that arises when the graft’s immune cells recognize the host as foreign and attack the recipient’s body cells. Its occurrence poses a major medical complication that limits the efficacy of HSCT and causes significant morbidity and mortality. New insights into the pathophysiology of GvHD have led to new developments in treatment strategies. Additionally, immediate survival is no longer the only concern after allogeneic HSCT (allo-HSCT). The burden of long-term morbidity borne by allo-HSCT survivors is substantial, and patients who received allo-HSCT have recently been identified as being at increased risk of cardiovascular events.

In this exclusive podcast, John Koreth, MBBS, PhD, of the Dana-Farber Cancer Institute, Boston, Massachusetts, Eduardo Rodríguez-Arbolí, MD, MPhil, Hospital Universitario Virgen del Rocío, Seville, Spain, and Eleni Gavriilaki, MD, PhD, of the National and Kapodistrian University of Athens, Greece, provide the latest transplant updates, as presented at this year’s Congress of the European Hematology Association (EHA 2021).

The post Latest transplant updates from EHA 2021 appeared first on VJHemOnc.

The treatment of multiple myeloma is a rapidly evolving field with advances in the understanding of myeloma disease biology contributing to the development of novel targeted therapies. Recently, there has been a rapid increase in the number of chimeric antigen receptor (CAR) T-cell therapies being trialed for patients with multiple myeloma, and in March 2021, idecabtagene vicleucel became the first CAR-T therapy to receive FDA approval for the treatment of myeloma.

In this podcast, Nina Shah of the University of California San Francisco, CA; Saad Usmani of the Levine Cancer Institute, NC; Sham Mailankody of the Memorial Sloan Kettering Cancer Centre, NY; Adam Cohen of the Abramson Cancer Centre, PA; and Maria-Victoria Mateos of the University Hospital of Salamanca, Spain, discuss the use of CAR-T therapy in patients with multiple myeloma.

The post Key updates on CAR-T therapy for multiple myeloma appeared first on VJHemOnc.

In this roundtable discussion, chaired by Gilles Salles, MD, PhD, Memorial Sloan Kettering, New York, NY; Nirav N. Shah, MD, Medical College of Wisconsin, Brookfield, WI; Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria; Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, review the most exciting updates in lymphoma from the 2021 European Hematology Association (EHA) and International Conference on Malignant Lymphoma (ICML) meetings, highlighting the latest data on antibody, cellular and novel therapies.

The post The Lymphoma Sessions: highlights from EHA and ICML 2021 appeared first on VJHemOnc.